Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients With Prostate Cancer on 18 F-Prostate-Specific Membrane Antigen PET/CT.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 35835124.
- Also identified by DOI 10.1097/RLU.0000000000004338.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 79-year-old man with rising prostate-specific antigen of 3.2 ng/mL and diagnosis of metastatic castration-resistant prostate cancer received abiraterone and prednisone for treatment regarding prostate-specific membrane antigen (PSMA)-avid bone lesions on PET/CT. Four months later, a follow-up 18 F-DCFPyL PET/CT demonstrated new and increased multifocal PSMA-avid osseous and liver lesions, whereas prostate-specific antigen was stabled at 3.1 ng/mL. Biopsy of liver lesion showed metastasis from a primary pancreatic acinar cell carcinoma. Retrospectively, PSMA-avid pancreatic body lesion was identified on both PSMA PET/CT scans. This case illustrated that any above background PSMA uptake in the pancreas warrants suspicion for malignancy.
Medical subject headings
- Prostatic Neoplasms
- Pancreatic Neoplasms